# Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)

> **NCT03953456** · PHASE2 · TERMINATED · sponsor: **Genfit** · enrollment: 17 (actual)

## Conditions studied

- Non-Alcoholic Fatty Liver

## Interventions

- **DRUG:** elafibranor 120mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03953456
- **Lead sponsor:** Genfit
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-08-16
- **Primary completion:** 2020-03-11
- **Final completion:** 2020-07-14
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Continuation of the trial cannot serve a scientific purpose
- **Last updated:** 2020-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03953456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03953456, "Study to Evaluate the Effect of Elafibranor on Hepatic Lipid Composition in Subjects With Nonalcoholic Fatty Liver (NAFL)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03953456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*